Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease cystic fibrosis
Symptom C0876973|lung infection
Sentences 71
PubMedID- 25957311 From clinical infections, including the chronic bacterial lung infections associated with cystic fibrosis that form a focus of my research, there is now abundant evidence suggesting that rapid evolution by infecting microbes contributes to host adaptation, treatment failure and worsening patient prognosis.
PubMedID- 20927769 Authors' conclusions: we could not identify an antibiotic adjuvant therapy that could be recommended for the treatment of lung infection in those with cystic fibrosis.
PubMedID- 20942647 Aeruginosa cell counts in a rat lung infection model and in patients with cystic fibrosis.
PubMedID- 25221853 Purpose of review: newer 'innovative' formulations of antibiotics for pseudomonas aeruginosa lung infection in patients with cystic fibrosis include colistimethate sodium and tobramycin in the form of dry powders for inhalation (dpis).
PubMedID- 22767545 Burkholderia cenocepacia is a member of the burkholderia cepacia complex (bcc), a group of gram-negative opportunistic pathogens that cause severe lung infections in patients with cystic fibrosis and display extreme intrinsic resistance to antibiotics, including antimicrobial peptides.
PubMedID- 24015256 Pseudomonas aeruginosa (pa) is an important bacterial pathogen causing acute nosocomial infections in immunocompromised patients, and chronic recurring lung infections in patients with cystic fibrosis (cf) or non-cf bronchiectasis .
PubMedID- 20019078 During the chronic lung infection of patients with cystic fibrosis (cf), pseudomonas aeruginosa can survive for long periods due to adaptive evolution mediated by genetic variation.
PubMedID- 22589289 It is also an important opportunistic human pathogen and major contributor to chronic lung infections in patients with cystic fibrosis (cf).
PubMedID- 26223882 Pseudomonas aeruginosa (pa) is an opportunistic gram-negative pathogen associated with nosocomial infections, acute infections and chronic lung infections in patients with cystic fibrosis.
PubMedID- 24709961 These strains are genetically diverse, differ from strains that cause chronic lung infections in patients with cystic fibrosis, and exhibit heterogeneous production of virulence factors in vitro.
PubMedID- 21303421 Biofilm-associated chronic pseudomonas aeruginosa lung infections in patients with cystic fibrosis are virtually impossible to eradicate with antibiotics because biofilm-growing bacteria are highly tolerant to antibiotics and host defense mechanisms.
PubMedID- 22540844 In conclusion, these data underline the importance of biofilm prevention strategies by early aggressive antibiotic prophylaxis or therapy before phenotypic diversification during chronic lung infection of patients with cystic fibrosis.
PubMedID- 23620120 Abscessus strains from cystic fibrosis patients with clinical lung infection.
PubMedID- 25786110 In humans, genetic evidence of the relevance of ptx3 in innate resistance has been described in pulmonary tuberculosis, in cystic fibrosis patients with p. aeruginosa lung infection and in invasive aspergillosis in patients undergoing hematopoietic stem-cell transplantation .
PubMedID- 26268854 The opportunistic pathogen pseudomonas aeruginosa causes chronic lung infection in patients with cystic fibrosis.
PubMedID- 25657265 Pandoraea is an emerging respiratory pathogen capable of causing chronic lung infections in people with cystic fibrosis (cf), but the clinical significance of this infection is ambiguous.
PubMedID- 22069491 Pseudomonas aeruginosa is an opportunistic pathogen that causes both acute pneumonitis in immunocompromised patients and chronic lung infections in individuals with cystic fibrosis and other bronchiectasis.
PubMedID- 24730990 Bacteria of the burkholderia cepacia complex are the cause of severe lung infections primarily in patients with cystic fibrosis (cf).
PubMedID- 20352425 For example, while pyo production by p. aeruginosa during lung infection of cystic fibrosis patients is correlated with a poor prognosis, it is also highly correlated with a lower incidence of yeast infections (lau et al.
PubMedID- 24064077 Bacterial sinusitis can be a focus for initial lung colonisation and chronic lung infection in patients with cystic fibrosis.
PubMedID- 21775220 Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis.
PubMedID- 24614401 We used antibiotic therapy of chronic lung infection in persons with cystic fibrosis as a model system to assess the influence of key variables of therapy on measures of microbial community perturbation.
PubMedID- 22022288 Aztreonam (for inhalation solution) for the treatment of chronic lung infections in patients with cystic fibrosis: an evidence-based review.
PubMedID- 23137712 Treatment of lung infection in patients with cystic fibrosis: current and future strategies.
PubMedID- 26517580 Neutrophil-associated inflammation during pseudomonas aeruginosa lung infection is a determinant of morbidity in cystic fibrosis (cf).
PubMedID- 22973562 Historically, pharmaceutical aerosols have been employed for the treatment of obstructive airway diseases, such as asthma and chronic obstructive pulmonary disease, but in the past decades their use has been expanded to treat lung infections associated with cystic fibrosis and other respiratory diseases.
PubMedID- 22715310 S. aureusis causing a range of acute and pyogenic infections, includingabscesses, central nervous system infections, endocarditis,osteomyelitis, pneumonia, urinary tract infections, chroniclung infections associated with cystic fibrosis, and severalsyndromes caused by exotoxins and enterotoxins, includingfood poisoning, scalded skin and toxic shock syndromes 1.
PubMedID- 25596784 cystic fibrosis with chronic lung infection, patients with chronic wound infections) or associated with devices (e.g.
PubMedID- 25494960 The ecotypes isolated from this long-term experimental evolution are similar to those commonly isolated from lung infections of persons with cystic fibrosis (cf) (zlosnik et al.
PubMedID- 22905192 It is a leading cause of acute pneumonia in hospitalized patients and is responsible for chronic lung infection in patients with cystic fibrosis.
PubMedID- 24034668 It is responsible for serious chronic and often fatal lung infections in patients with cystic fibrosis and acute infections in patients that are immune compromised or have serious burns 1.
PubMedID- 22208544 Commercial availability of more than one inhaled antibiotic for the management of chronic pseudomonas aeruginosa lung infections in persons with cystic fibrosis creates a welcome question: can different inhaled therapies be combined to improve patient outcomes.
PubMedID- 23533140 Overproduction of alginate, also known as mucoidy, affords the bacterium protection from the host's defenses and facilitates the establishment of chronic lung infections in individuals with cystic fibrosis.
PubMedID- 25830686 Maltophilia lung infection in patients with cystic fibrosis.
PubMedID- 23848942 The membrane filter biofilm model mirrored biofilms in environmental habitats as found in soil or on leaves and also biofilms involved in infections as for example lung infections of cystic fibrosis patients .
PubMedID- 26430738 P. aeruginosa causes life-threatening community-acquired pneumonia, nosocomial infections such as pneumonia, urinary tract infections, and bacteremia; and chronic lung infections in patients with cystic fibrosis 7.
PubMedID- 21930755 Genotypic and phenotypic variation in pseudomonas aeruginosa reveals signatures of secondary infection and mutator activity in certain cystic fibrosis patients with chronic lung infections.
PubMedID- 22968160 Fluoroquinolones are commonly used to treat lung infections in patients with cystic fibrosis.
PubMedID- 26371010 In practice, biofilms can be found in association with chronic bacterial infections generally, wound infections, chronic lung infections of cystic fibrosis patients, in association with in-dwelling devices such as catheters, or on environmental surfaces, e.g., .
PubMedID- 23737089 Authors' conclusions: we could not identify an antibiotic adjuvant therapy that could be recommended for the treatment of lung infection in those with cystic fibrosis.
PubMedID- 25806622 Biofilms play important roles in human infections including native valve endocarditis, otitis media, chronic bacterial prostatitis, lung infections in patients with cystic fibrosis and periodontitis .
PubMedID- 22196973 Pseudomonas aeruginosa is the major pathogen in chronic lung infections of individuals with cystic fibrosis (cf).
PubMedID- 20503281 Pseudomonas aeruginosa (psa) is the most common pathogen to cause chronic lung infection in children with cystic fibrosis (cf), and is associated with an increase in both morbidity and mortality.
PubMedID- 26253522 Pseudomonas aeruginosa causes chronic lung infections in people with cystic fibrosis (cf) and acute opportunistic infections in people without cf.
PubMedID- 20948804 It is also the leading bacterial cause of acute ventilator-associated pneumonia and chronic lung infections in patients with cystic fibrosis (cf).
PubMedID- 22230402 Aeruginosa causes chronic lung infection in individuals with cystic fibrosis and nosocomial pneumonia resulting in significant morbidity and mortality.
PubMedID- 20218338 Identification of possible mechanisms of lung infection in patients with cystic fibrosis will allow to develop evidence-based system of prevention of infectious complications in these patients.
PubMedID- 23403223 Abscessus lung infection in patients with cystic fibrosis.
PubMedID- 22798960 The β-hairpin mimetic pol7080 is currently in a phase i clinical trial in europe, and could represent an important drive in the treatment of chronic lung infections in patients with cystic fibrosis where p. aeruginosa plays a crucial role.
PubMedID- 24260360 A particularly serious medical problem caused by p. aeruginosa is chronic lung infection associated with cystic fibrosis .

Page: 1 2